Tagged with UCB

Switzerland Switzerland is the 22nd biggest country in Europe in terms of population yet plays host to a full 20 percent of the continent’s life science companies, with over 1,000 operational firms. Over 0.5 percent of the entire Swiss population (48,000 out of 8.8 million) work in the life sciences, 67…

Switzerland Intricacy, precision, and quality. These are bywords for Switzerland’s world-renowned watchmaking industry, but which could equally apply to its biopharmaceutical manufacturing footprint. As with top-end models from Rolex, Tag Heuer, or Breitling, made-in-Switzerland pharmaceuticals do not necessarily come cheap, but the country’s network of life science manufacturers seem content that…

Switzerland Fabrice Véricel and Geoffrey Folie explore UCB’s strategic growth, highlighting its European sites in Braine-l’Alleud, Belgium and Bulle, Switzerland and their roles in global pharmaceutical production. Key topics include the transition to biologics, embracing AI for process optimization, and sustainability initiatives.   Biomanufacturing thrives on complexity and collaboration, offering intellectual…

APAC A run-through of some of the most striking recent stories from pharma in the dynamic Asia-Pacific region, including Japan’s attempts to bring back Big Pharma investment; UCB’s decision to divest its China neurology and allergy business for USD 680 million; and Pfizer, AstraZeneca and Novartis investing in Singaporean manufacturing.  …

Global UCB has been undergoing a far-reaching digital business transformation, integrating novel approaches across its R&D organisation, including Computer-Aided Drug Design (CADD) and AI, while striving to maintain a patient-centric focus. Speaking at the recent FT Global Pharma and Biotech Summit, CEO Jean-Christophe Tellier discussed the Belgian midcap’s digital undertakings and…

Italy Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in the country’s National Recovery and Resilience Plan and a priority within its healthcare modernisation plans.   Novel solutions came out…

Italy UCB Italy’s Managing Director, Federico Chinni offeres his insights into UCB’s positioning and its new product launches, the first for the company in ten years. He also weighs in on Italy’s national Recovery and Resilience Plan and explains how the company was ready for digitalisation even before the pandemic.  Our…

Spain UCB’s general manager for Iberia, Pau Ricós, comments on the Belgian company’s upcoming launches, its focus on immunology and neurology, and the importance of R&D – UCB spent around 28 percent of its revenues on R&D in 2021. In addition, Ricós analyses Spain’s slow access to innovation and the pros…

Switzerland Belgian champion UCB’s global manufacturing head, Jacques Marbehant, talks candidly about managing a broad global manufacturing and supply chain through the COVID-19 pandemic, the talent challenges inherent in scaling up manufacturing capacity and scope, and why greater levels of both internal and external collaboration are crucial for the pharma industry…

Mexico UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental diseases, and the abundant opportunities that Mexico and the region carries for the firm.   The upcoming three years are crucial and UCB Mexico wants to play a role elevating…

Belgium After reaching revenues of EUR 2.323 billion in the first six months of 2019, UCB announced on December 18 that it will build an innovative multi-product biological manufacturing facility on their site in Braine l’Alleud, Wallonia, Belgium.   Headquartered in Brussels, UCB is a global biopharmaceutical company developing innovative medicines…

Belgium Jean-Christophe Tellier became UCB’s CEO on January 1, 2015 only a few years joining the company in 2011. Before taking on the role Tellier held positions as executive VP of European Operations and later successfully led UCB’s BioBrands and Solutions division as executive VP as well.   Tellier was trained…